{"entity":{"type":"insider","cik":"0001675232","url":"/insider/0001675232","json_url":"/insider/0001675232.json","name":"Hatteras Venture Partners IV SBIC, LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":16,"n_filings":5,"first":"2016-06-07","last":"2018-06-01","span_basis":"filed_date"},"name_variants":[{"name":"Hatteras Venture Partners IV SBIC, LP","source":"filing","n_filings":5,"first_seen":"2016-06-07","last_seen":"2018-06-01"}],"transactions":[{"id":6016951,"accession":"0001209191-18-034839","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-034839","line_url":"/filing/0001209191-18-034839#line-2","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"LEE KENNETH B JR; Thorp Clay; Hatteras Venture Partners IV SBIC, LP; Crumpler John; Hatteras Venture Advisors IV SBIC, LLC; Reed Douglas MD; INGRAM ROBERT ALEXANDER","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":758290.0,"shares_display":"758,290","price_per_share":48.0,"price_display":"48.00","price_state":"stated","total_value":36397920.0,"total_display":"36,397,920.00","shares_owned_after":3279421.0,"shares_owned_after_display":"3,279,421","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-30","filed_date":"2018-06-01","scope":"insider"},{"id":6016949,"accession":"0001209191-18-034839","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-034839","line_url":"/filing/0001209191-18-034839#line-1","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"LEE KENNETH B JR; Thorp Clay; Hatteras Venture Partners IV SBIC, LP; Crumpler John; Hatteras Venture Advisors IV SBIC, LLC; Reed Douglas MD; INGRAM ROBERT ALEXANDER","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41710.0,"shares_display":"41,710","price_per_share":48.0,"price_display":"48.00","price_state":"stated","total_value":2002080.0,"total_display":"2,002,080.00","shares_owned_after":3237711.0,"shares_owned_after_display":"3,237,711","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-30","filed_date":"2018-06-01","scope":"insider"},{"id":6454685,"accession":"0001209191-18-032789","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789#line-8","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":474.0,"shares_display":"474","price_per_share":50.5,"price_display":"50.50","price_state":"stated","total_value":23937.0,"total_display":"23,937.00","shares_owned_after":4037737.0,"shares_owned_after_display":"4,037,737","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-23","filed_date":"2018-05-23","scope":"insider"},{"id":6454682,"accession":"0001209191-18-032789","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789#line-7","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26.0,"shares_display":"26","price_per_share":50.5,"price_display":"50.50","price_state":"stated","total_value":1313.0,"total_display":"1,313.00","shares_owned_after":4037711.0,"shares_owned_after_display":"4,037,711","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-23","filed_date":"2018-05-23","scope":"insider"},{"id":6454679,"accession":"0001209191-18-032789","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789#line-6","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5592.0,"shares_display":"5,592","price_per_share":50.8593,"price_display":"50.86","price_state":"stated","total_value":284405.2056,"total_display":"284,405.21","shares_owned_after":4038519.0,"shares_owned_after_display":"4,038,519","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-22","filed_date":"2018-05-23","scope":"insider"},{"id":6454676,"accession":"0001209191-18-032789","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789#line-5","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":308.0,"shares_display":"308","price_per_share":50.6851,"price_display":"50.69","price_state":"stated","total_value":15611.0108,"total_display":"15,611.01","shares_owned_after":4038211.0,"shares_owned_after_display":"4,038,211","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-22","filed_date":"2018-05-23","scope":"insider"},{"id":6454673,"accession":"0001209191-18-032789","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789#line-4","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29005.0,"shares_display":"29,005","price_per_share":51.1604,"price_display":"51.16","price_state":"stated","total_value":1483907.402,"total_display":"1,483,907.40","shares_owned_after":4046206.0,"shares_owned_after_display":"4,046,206","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-21","filed_date":"2018-05-23","scope":"insider"},{"id":6454670,"accession":"0001209191-18-032789","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789#line-3","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1595.0,"shares_display":"1,595","price_per_share":51.0589,"price_display":"51.06","price_state":"stated","total_value":81438.9455,"total_display":"81,438.95","shares_owned_after":4044611.0,"shares_owned_after_display":"4,044,611","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-21","filed_date":"2018-05-23","scope":"insider"},{"id":6454667,"accession":"0001209191-18-032789","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789#line-2","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":474.0,"shares_display":"474","price_per_share":52.13,"price_display":"52.13","price_state":"stated","total_value":24709.62,"total_display":"24,709.62","shares_owned_after":4044137.0,"shares_owned_after_display":"4,044,137","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-21","filed_date":"2018-05-23","scope":"insider"},{"id":6454662,"accession":"0001209191-18-032789","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789#line-1","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26.0,"shares_display":"26","price_per_share":52.13,"price_display":"52.13","price_state":"stated","total_value":1355.38,"total_display":"1,355.38","shares_owned_after":4044111.0,"shares_owned_after_display":"4,044,111","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-21","filed_date":"2018-05-23","scope":"insider"},{"id":4783134,"accession":"0001209191-17-035173","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-17-035173","line_url":"/filing/0001209191-17-035173#line-4","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Hatteras Venture Advisors IV SBIC, LLC; LEE KENNETH B JR; Reed Douglas MD; Hatteras Venture Partners IV SBIC, LP; Crumpler John; INGRAM ROBERT ALEXANDER; Thorp Clay","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":133333.0,"shares_display":"133,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":1999995.0,"total_display":"1,999,995.00","shares_owned_after":3861797.0,"shares_owned_after_display":"3,861,797","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-05-22","filed_date":"2017-05-24","scope":"insider"},{"id":4263590,"accession":"0001578563-17-000004","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001578563-17-000004","line_url":"/filing/0001578563-17-000004#line-3","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC; Thorp Clay; Reed Douglas MD; INGRAM ROBERT ALEXANDER; Crumpler John; LEE KENNETH B JR","owner_url":null,"role":"Ten percent owner, Other","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7592.0,"shares_display":"7,592","price_per_share":8.22,"price_display":"8.22","price_state":"stated","total_value":62406.24,"total_display":"62,406.24","shares_owned_after":2060514.0,"shares_owned_after_display":"2,060,514","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-01-19","filed_date":"2017-01-19","scope":"insider"},{"id":4263587,"accession":"0001578563-17-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001578563-17-000004","line_url":"/filing/0001578563-17-000004#line-2","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC; Thorp Clay; Reed Douglas MD; INGRAM ROBERT ALEXANDER; Crumpler John; LEE KENNETH B JR","owner_url":null,"role":"Ten percent owner, Other","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12258.0,"shares_display":"12,258","price_per_share":8.64,"price_display":"8.64","price_state":"stated","total_value":105909.12,"total_display":"105,909.12","shares_owned_after":2068106.0,"shares_owned_after_display":"2,068,106","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-01-18","filed_date":"2017-01-19","scope":"insider"},{"id":4263584,"accession":"0001578563-17-000004","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001578563-17-000004","line_url":"/filing/0001578563-17-000004#line-1","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC; Thorp Clay; Reed Douglas MD; INGRAM ROBERT ALEXANDER; Crumpler John; LEE KENNETH B JR","owner_url":null,"role":"Ten percent owner, Other","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9806.0,"shares_display":"9,806","price_per_share":8.92,"price_display":"8.92","price_state":"stated","total_value":87469.52,"total_display":"87,469.52","shares_owned_after":2080364.0,"shares_owned_after_display":"2,080,364","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-01-17","filed_date":"2017-01-19","scope":"insider"},{"id":2959330,"accession":"0001209191-16-126262","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-16-126262","line_url":"/filing/0001209191-16-126262#line-3","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Hatteras Venture Advisors IV SBIC, LLC; Reed Douglas MD; LEE KENNETH B JR; Hatteras Venture Partners IV SBIC, LP; Crumpler John; Thorp Clay; INGRAM ROBERT ALEXANDER","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":69.0,"shares_display":"69","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":483.0,"total_display":"483.00","shares_owned_after":1675884.0,"shares_owned_after_display":"1,675,884","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-07","filed_date":"2016-06-07","scope":"insider"},{"id":2959324,"accession":"0001209191-16-126262","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-126262","line_url":"/filing/0001209191-16-126262#line-2","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Hatteras Venture Advisors IV SBIC, LLC; Reed Douglas MD; LEE KENNETH B JR; Hatteras Venture Partners IV SBIC, LP; Crumpler John; Thorp Clay; INGRAM ROBERT ALEXANDER","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":414286.0,"shares_display":"414,286","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":2900002.0,"total_display":"2,900,002.00","shares_owned_after":2090170.0,"shares_owned_after_display":"2,090,170","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-07","filed_date":"2016-06-07","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001560241","name":"G1 Therapeutics, Inc.","url":"/issuer/0001560241","role":"Ten percent owner","n_filings":3,"first_seen":"2017-05-24","last_seen":"2018-06-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001539029","name":"Clearside Biomedical, Inc.","url":"/issuer/0001539029","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2016-06-07","last_seen":"2017-01-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001675232","retrieved_at":"2026-08-21T03:39:50+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-19","last_ingest":"2026-08-20T05:22:56.381658+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}